Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Don C. Rockey, Andrew H. Beck, Murray B. Resnick, Nezam H. Afdhal, Michael Christopher Montalto, Oscar Carrasco-Zevallos, Catherine Jia, Zachary Goodman, Harsha Pokkalla, Mitchell L. Shiffman, Zahil Shanis, Ling Han, Jaime Bosch, Manal F. Abdelmalek, Arun J. Sanyal, Quang Huy Le, Chuhan Chung, Robert P. Myers, Ilan Wapinski, Stephen A. Harrison, Dinkar Juyal
Publikováno v:
Bosch, Jaime; Chung, Chuhan; Carrasco-Zevallos, Oscar M; Harrison, Stephen A; Abdelmalek, Manal F; Shiffman, Mitchell L; Rockey, Don C; Shanis, Zahil; Juyal, Dinkar; Pokkalla, Harsha; Le, Quang Huy; Resnick, Murray; Montalto, Michael; Beck, Andrew H; Wapinski, Ilan; Han, Ling; Jia, Catherine; Goodman, Zachary; Afdhal, Nezam; Myers, Robert P; ... (2021). A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis. Hepatology, 74(6), pp. 3146-3160. Wiley 10.1002/hep.32087
BACKGROUND AND AIMS The hepatic venous pressure gradient (HVPG) is the standard for estimating portal pressure but requires expertise for interpretation. We hypothesized that HVPG could be extrapolated from liver histology using a machine learning (M
Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD
Autor:
Jiayin Zheng, Anna Mae Diehl, Cynthia D. Guy, Ayako Suzuki, Kara Wegermann, Allison E. Ashley-Koch, Shein-Chung Chow, Andrea D. Coviello, Melanie E. Garrett, Cynthia A. Moylan, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications, Vol 5, Iss 4, Pp 598-607 (2021)
Hepatology Communications
Hepatology Communications
The development of fibrosis in nonalcoholic fatty liver disease (NAFLD) is influenced by genetics, sex, and menopausal status, but whether genetic susceptibility to fibrosis is influenced by sex and reproductive status is unclear. Our aim was to iden
Autor:
Guadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, Marwan Ghabril, Mitchell L. Shiffman, Ziad H. Younes, Paul J. Thuluvath, Annalisa Berzigotti, Agustin Albillos, James M. Robinson, David T. Hagerty, Jean L. Chan, Arun J. Sanyal, M. Abdelmalek, K. Bhamidimarri, B. Borg, S. Caldwell, J. Fenkel, B. Freilich, M. Fuchs, M. Ghabril, R. Ghalib, S. Gonzalez, S. Gordon, B. Hameed, S. Harrison, Z. Kayali, N. Kemmer, K. Korenblat, M. Lai, C. Landis, E. Lawitz, W. Lee, S. Lidofsky, E. Mena, M. Noureddin, A. Paredes, N. Pyrsopoulos, R. Reddy, M. Rinella, D. Rockey, M. Rodriguez, M. Ryan, S. Sarkar, S. Satapathy, A. Scanga, M. Shiffman, M. Siddiqui, D. Simonetto, W. Syn, P. Thuluvath, R. Vemulapalli, J. Vierling, Z. Younes, A. Albillos, J. Arenas Ruiz-Tapiador, S. Augustin, J. Calleja, J. Crespo Garcia, L. Garcia Buey, J.C. Garcia-Pagan, C. Villanueva, C. Bureau, N. Carbonell, V. Leroy, P.-E. Rautou, H. Heinzow, I. Schiefke, A. Zipprich, A. Berzigotti, B. Muellhaupt
Publikováno v:
Garcia-Tsao, Guadalupe; Bosch, Jaime; Kayali, Zeid; Harrison, Stephen A; Abdelmalek, Manal F; Lawitz, Eric; Satapathy, Sanjaya K; Ghabril, Marwan; Shiffman, Mitchell L; Younes, Ziad H; Thuluvath, Paul J; Berzigotti, Annalisa; Albillos, Agustin; Robinson, James M; Hagerty, David T; Chan, Jean L; Sanyal, Arun J (2020). Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. Journal of hepatology, 72(5), pp. 885-895. Elsevier 10.1016/j.jhep.2019.12.010
Background & Aims Emricasan, an oral pan-caspase inhibitor, decreased portal pressure in experimental cirrhosis and in an open-label study in patients with cirrhosis and severe portal hypertension, defined as a hepatic venous pressure gradient (HVPG)
Autor:
Elizabeth K. Fletcher, Athan Kuliopulos, Nga Nguyen, Srijoy Guha, Andrew Shearer, Daniel H. Cox, James D. Baleja, Ying Wang, Manal F. Abdelmalek, Lidija Covic, Rajashree Rana
Publikováno v:
Molecular Metabolism, Vol 29, Iss, Pp 99-113 (2019)
Molecular Metabolism
Molecular Metabolism
Objective Increases in hepatic and plasma cholesterol occur in patients with nonalcoholic fatty liver disease (NAFLD), although the reason for this is not well understood. We investigated whether Protease-Activated Receptor 2 (PAR2) plays a role in c
Autor:
Jun Zhang, Roger J. Davis, Meng Li, Christopher Q. Chen, Anna Mae Diehl, Mariam Aghajan, Ying Wang, Robert Win Maw Min, Tin Aung Than, Sanda Win, Neil Kaplowitz, Yibu Chen, Manal F. Abdelmalek, Filbert W.M. Aung, Ayako Suzuki
Publikováno v:
Journal of Clinical Investigation. 129:5278-5293
SH3 domain–binding protein that preferentially associates with Btk (SAB) is an outer-membrane docking protein for JNK-mediated impairment of mitochondrial function. Deletion of Sab in hepatocytes inhibits sustained JNK activation and cell death. Th
Autor:
De Lisa Fairweather, Sanda Win, Stefano Ballestri, Tin Aung Than, Amedeo Lonardo, Fabio Nascimbeni, Ayako Suzuki, Manal F. Abdelmalek
Publikováno v:
Hepatology
Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and d
Autor:
Anna Mae Diehl, Oliver Glass, Elizabeth Bechard, Jane F. Pendergast, Cynthia D. Guy, Daniel Liu, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers an
Autor:
Cynthia D. Guy, Ying Wang, Anna Mae Diehl, Dana Portenier, Dawn Piercy, Matthew J Crowley, Andrea D. Coviello, Anastasia-Stefania Alexopoulos, Ranjan Sudan, Cynthia A. Moylan, Manal F. Abdelmalek, Keri A. Seymour, Ricardo Henao
Publikováno v:
Hepatology (Baltimore, Md.). 74(3)
BACKGROUND AND AIMS Whether glycemic control, as opposed to diabetes status, is associated with the severity of NAFLD is open for study. We aimed to evaluate whether degree of glycemic control in the years preceding liver biopsy predicts the histolog
Autor:
C. Stephen Djedjos, Raul Aguilar Schall, Zachary Goodman, B. Mccolgan, G. Mani Subramanian, Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, Vlad Ratziu, Zobair M. Younossi, Manal F. Abdelmalek, Arun J. Sanyal, Stephen H. Caldwell, Mitchell L. Shiffman, Catherine Jia, John G. McHutchison, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Hepatology
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridg
Autor:
Manal F. Abdelmalek, Margery A. Connelly, Stephen J. Rossi, Mary E. Rinella, Angelo H. Paredes, Stephen A. Harrison, Lei Ling, James F. Trotter, Mark J. Jaros, Alex M. DePaoli
Publikováno v:
Journal of Hepatology. 70:735-744
NGM282, an engineered analogue of the gut hormone FGF19, improves hepatic steatosis and fibrosis biomarkers in patients with non-alcoholic steatohepatitis (NASH). However, NGM282 increases serum cholesterol levels by inhibiting CYP7A1, which encodes